OmniAb Inc. (OABI)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at OmniAb Inc..
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 2.00 $ — 46% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/04/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
This stock currently pays no dividend.
Quality & Screener
AAQS
4/10The AAQS (AlleAktien Quality Score) checks 10 quality criteria on growth, profitability, and balance-sheet strength — per the methodology developed and published by AlleAktien, calculated by us from our own fundamental data. A stock counts as a quality stock from 9 out of 10 points. Where a company has a shorter listing history, we calculate over the fiscal years available (at least five).
- Sales growth 10Y > 5% 0.3%
- Exp. sales growth 3Y > 5% 57.1%
- EBIT growth 10Y > 5% –
- Exp. EBIT growth 3Y > 5% 57.1%
- Net debt < 4x EBIT –
- EBIT positive, 10Y straight 0
- Max. EBIT decline < 50% –
- Return on equity > 15% -111.9%
- ROCE > 15% -25.1%
- Expected return > 10% 37.2%
View all AAQS quality stocks · Read the methodology at AlleAktien
Source: fundamental data
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Growth Score
3 of 10 Weak growthTen checks against the annual reports — each one passed counts a point.
- Revenue grows by more than 15% a year over three years -31.9% failed
- More than 10% revenue growth is expected for the coming year 49.7% passed
- Share count grows by less than 3% a year 10.0% failed
- Revenue growth plus cash-flow margin add up to at least 40 ("Rule of 40") -227.6% failed
- Gross margin at 40% or higher and without meaningful erosion -18.2% failed
- Goodwill from acquisitions does not grow faster than revenue 27.9% failed
- Net debt below twice EBITDA 34 m net cash passed
- Operating cash flow covers the profits of the last three years 104 m failed
- Return on capital at 15% or higher, or up versus two years ago -25.1% failed
- Insiders hold at least 10% or are net buyers 15.3% passed
A criterion without figures counts neither as passed nor as failed; a score is only produced from 7 judgeable criteria upwards. Source: fundamental data. All ten criteria in detail
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 266.5% above the current price.
- Consensus
- Strong Sell
- Analyst Ratings
- 8
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | -0.42 | -0.43 – -0.40 | 31 | 27.0% | 5 |
| 12/31/2027 | -0.32 | -0.43 – -0.19 | 46 | 22.5% | 4 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- -0.11 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.12 | – | 11 | 124.10 | -121.00 | -4 | -4 |
| 2025: Q1 | -0.17 | – | 4 | 9.30 | -438.10 | -16 | -16 |
| 2025: Q2 | -0.15 | – | 4 | -48.80 | -407.40 | -5 | -5 |
| 2025: Q3 | -0.14 | – | 2 | -46.30 | -738.10 | -10 | -10 |
| 2025: Q4 | -0.11 | – | 8 | -22.50 | -169.30 | -6 | -6 |
| 2026: Q1 | -0.06 | – | 14 | 246.70 | -53.50 | -5 | -5 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2019 | 18 | -13 | -14 | -0.12 | -5 | 218 | 262 |
| 2020 | 23 | -26 | -18 | -0.15 | 4 | 236 | 295 |
| 2021 | 35 | -36 | -27 | -0.24 | -6 | 234 | 304 |
| 2022 | 59 | -27 | -22 | -0.26 | -4 | 341 | 421 |
| 2023 | 34 | -69 | -51 | -0.51 | 2 | 315 | 375 |
| 2024 | 26 | -75 | -62 | -0.61 | -40 | 288 | 326 |
| 2025 | 19 | -72 | -65 | -0.57 | -36 | 267 | 301 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
OmniAb, Inc., ein Biotechnologieunternehmen, lizenziert Discovery-Research-Technologie an Pharma- und Biotech-Unternehmen sowie akademische Einrichtungen, um die Entdeckung von Therapeutika in den USA, Europa, Japan, China und Kanada zu ermöglichen.
| Employees | 89 |
|---|---|
| Headquarters | EmeryVille, CA |
| Address | 5980 Horton Street, 94608 EmeryVille, United States |
| Phone | 510 250 7800 |
| Website | omniab.com |
| IPO Date | 2. Nov 2022 |
| ISIN | US68218J1034 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Matthew W. Foehr | President, CEO & Director | 1973 |
| Kurt A. Gustafson | Executive VP of Finance & CFO | 1968 |
| Charles S. Berkman J.D. | Chief Legal Officer | 1969 |
| Amechi Nwachuku | Executive VP & Chief Operating Officer | 1975 |
| Cia McCaffrey | Senior Vice President of People & Talent | – |
| Bill Harriman Ph.D. | Senior Vice President of Discovery Partnership Mgt., Technology Development & Operations | – |
| Christel Iffland Ph.D. | Senior Vice President of R&D Portfolio Management and Technology Operations | – |
| Yasmina Noubia Abdiche Ph.D. | Senior Vice President of Exploratory Research | – |
| Bob Chen | Senior Vice President of Discovery Systems | – |
| Todd Pettingill C.F.A. | Vice President of Business Development & Strategy | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: August 3, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.